United Therapeutics Corporation (NASDAQ: UTHR) reported positive results from a phase 1 study of miroliverELAP, an external liver assist product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE